Doença Hepática Alcoólica (DHA)

Autores

  • Luís Costa Matos Interno do Internato Complementar de Medicina Interna Serviço de Medicina I do Hospital São Teotónio S.A. - Viseu

Palavras-chave:

Doença Hepática Alcoólica, Esteatose Hepática, Hepatite Alcoólica, Cirrose Hepática

Resumo

A Doença Hepática Alcoólica (DHA) é um problema de saúde
pública em Portugal, sendo o álcool a droga de abuso mais frequente no nosso país. O autor apresenta uma revisão da literatura
sobre o tema, abordando a epidemiologia da DHA, a patogenia
da agressão hepática pelo álcool, o diagnóstico, e finalmente o
espectro da DHA desde a esteatose hepática, passando pela
hepatite alcoólica até à cirrose, com breves referências aos
avanços no tratamento destas entidades.

Downloads

Não há dados estatísticos.

Referências

Mª Lucília Mercês de Mello et al. Álcool e problemas ligados ao álcool em Portugal: Direcção Geral de Saúde 2001.

World Drink Trends 2004, WARC Ltd, ISBN: 1-84116-152-7.

World Drink Trends 1998, NTC publications, ISBN: 1-84116-016-4.

World Drink Trends 2002, WARC Ltd, UK, ISBN: 1-84116-105-5.

Adams WL et al. Alcohol-related hospitalizations of elderly people. Prevalence and geographic variation in the United States. JAMA 1993;270(17):2055.

Dias P et al. Patologia relacionada com o álcool no internamento de um Serviço de Medicina Interna. Med-interna. 2005; 9 (19): 32-36.

Risco de morrer em Portugal 2001, disponível em www.dgsaude.pt.

Sheila Sherlock & James Dooley, Diseases of the Liver and Biliary System, 11ª edição, Blackwell Publishing. 2002: 381-398.

Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci. 1975;252:85-105.

Mann R et al. The Epidemiology of Alcoholic Liver Disease, disponível em http://eeeniaa.nih.gov/publications/arh27-3/209-219.htm.

Bellentani S et al. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001 ;35(4):531-537.

Bode C et al. Effect of the type of beverage and meat consumed by alcoholics with alcoholic liver disease. Alcohol Clin Exp Res, 1998;22(8):1803-1805.

Pelletier S et al. Wine consumption is not associated with a decreased risk of alcoholic cirrhosis in heavy drinkers. Alcohol Alcohol 2002; 37(6):618-621.

Lieber C: Medical Disorders of Alcoholism. N Engl J Med 1995; 333:1058-1065.

Cederbaum AI: Effects of alcohol on hepatic mitochondrial function and DNA. Grastroenterology. 1999; 117 (1): 265-269.

Vidali M et al. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003 ;37(2):410-419.

Hoeck, JB. Endotoxin and alcoholic liver disease: tolerance and susceptibility. Hepatology 1999 ;29(5):1602-1604.

Han DW: Intestinal endotoxemia as a pathogenic mechanism in liver failure. World J Gastroenterol 2002;8(6);961-965.

Rao RK et al. Recent advances in Alcoholic Liver Disease: Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;286(6):G881-884.

Morgan MY et al. Sex-related differences among 100 patients with alcoholic liver disease. Br Med J 1977;1(6066):939-941.

Marshall AW et al. Ethanol elimination in males and females: relationship to menstrual cycle and body composition. Hepatology 1983 ;3(5):701-706.

Chrostek L et al. Gender-related differences in hepatic activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in humans. J Clin Lab Anal 2003;17(3):93-96.

Tanaka F et al. High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Hepatology 1996;23(2):234-239.

Borras E et al. Genetic polymorphism of alcohol dehydrogenase in europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. Hepatology 2000 ;31(4):984-989.

Savolainen VT et al. Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J Hepatol 1997 ;26(1):55-61.

Grove J et al. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997 ;26(1):143-146.

Casanova P et al. PGA: Marcador biológico de doença hepática alcoólica. Arq-Med 1996;10(1):10-13.

Casanova P : Esteatose Hepática Alcoólica. Álcool e Aparelho Digestivo - Biblioteca Gastroenterológica. Ed. Única, Permanyer Portugal. 2000: 79-90. ESBN: 972-733-066-5.

Mihas AA et al. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci 1992 ;303(6):415-428.

Santos R: Fibrose Hepática Alcoólica.. Álcool e Aparelho Digestivo - Biblioteca Gastroenterológica. Ed. Única, Permanyer Portugal. 2000: 91-115. ISBN: 972-733-066-5.

Poynard T et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991;100(5 Pt 1):1397-1402

Huang Y et al. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol 1996 ;24(4):377-384.

Fromerty B et al: Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 1995 ;108(1):193-200.

Santos A: Hepatite Alcoólica Aguda. Álcool e Aparelho Digestivo - Biblioteca Gastroenterológica. Ed. Única, Permanyer Portugal. 2000: 128-46. ISBN: 972-733-066-5.

Harrison´s Principles of Internal Medicine, 16th edition, McGraw-Hill 2005.

Dunn W et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005 ;41(2):353.

Cabre E et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990;98(3):715-720.

Carithers RL et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med

;110(9):685-690.

Akriviadis E et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1637-1648.

Tilg H et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003 ;38(4):419-425.

Naveau S et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39(5):1390-1397.

Heemann U et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002 ;36(4

Pt 1):949-958.

Stephen F et al The management of alcoholic liver disease. Journal of Hepatology, Vol. 38 (S1) (2003) pp. S2-S13.

Porto A: Cirrose hepática alcoólica. Álcool e Aparelho Digestivo - Biblioteca Gastroenterológica. Ed. Única, Permanyer Portugal. 2000: 117-27. ISBN: 972-733-066-5.

Henriques, P: Terapêutica Médica da Cirrose Hepática. Coimbra Med. 1981; 2 (1): 77-81.

Orrego H et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987;317(23):1421-1427.

Orrego H et al. Long-term treatment of alcoholic liver disease with propylthiouracil. Part 2: Influence of drop-out rates and of continued alcohol consumption in a clinical trial. J Hepatol 1994 ;20(3):343-349.

Mato JM et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30(6):1081-1089

Ficheiros Adicionais

Publicado

29-09-2006

Como Citar

1.
Costa Matos L. Doença Hepática Alcoólica (DHA). RPMI [Internet]. 29 de Setembro de 2006 [citado 4 de Novembro de 2024];13(3):207-16. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/1649

Edição

Secção

Artigos de Revisão

Artigos mais lidos do(s) mesmo(s) autor(es)